This segment focused on the research and development of novel therapeutics for the treatment of various cancers, with a strong emphasis on immuno-oncology. Key activities included preclinical studies, clinical trials (Phase 1, 1b, and 2), and biomarker analysis to identify patient populations most likely to respond to treatment. The lead product candidate, CMP-001, a CpG-A oligonucleotide TLR9 agonist, was investigated in combination with checkpoint inhibitors like pembrolizumab and nivolumab. The goal was to overcome resistance to PD-1 blockade and enhance anti-tumor immune responses. This segment aimed to improve patient outcomes in melanoma and other solid tumors by developing innovative immunotherapeutic strategies. The acquisition by Regeneron Pharmaceuticals provided significant resources and expertise to further advance these programs.